MedTrace Logo

Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer

NCT00154700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2005-12-20

No results posted yet for this study

Summary

The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Paclitaxel,Cisplatin,5-Fu,Folic Acid

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ann-Lii Cheng, M.D., Ph.D. · Department of Oncology, National Taiwan University hospital

  • Ann-Lii Cheng, M.D.,Ph.D · Department of Oncology, National Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2005-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154700 on ClinicalTrials.gov